BCAL Diagnostics Embeds Cancer Test Referrals Into 97% of Australian GP Software
BCAL Diagnostics embeds cancer test referrals into 97% of Australian GP software
BCAL Diagnostics Limited (ASX: BDX) has materially expanded its commercial reach by embedding clinical referral forms into the two GP software platforms that together cover approximately 97% of Australian general practitioners. The move marks a significant commercial infrastructure moment, giving the company a national primary care access pathway for its early cancer detection test portfolio. Alongside the GP integration, BCAL has simultaneously activated specialist software, a telehealth platform, and international market registrations, with a Sydney CBD clinic also in the pipeline.
When big ASX news breaks, our subscribers know first
A multi-channel commercial platform built for scale
GP and specialist software integration
Best Practice and Medical Director are the two dominant GP clinical software systems in Australia, and BCAL’s referral forms are now live across both. Together, they reach an estimated 97% of Australian general practitioners, positioning primary care as a scaled referral funnel for the company’s tests.
Beyond GPs, BCAL has also integrated with Genie (Magentus), described as Australia’s leading specialist practice management platform, extending the referral network further into specialist clinical workflows. The fulfilment backbone supporting these referrals draws on BCAL’s existing laboratory and distribution arrangements with Sonic Healthcare and Helius Pathology networks.
The full channel stack now activated includes:
- GP software referral forms (Best Practice and Medical Director)
- Specialist platform integration (Genie/Magentus)
- Telehealth service (EarlyDetection.com.au via Medmate, live 12 May 2026)
- Sydney CBD Centre for Early Detection clinic (opening)
EarlyDetection.com.au telehealth launch
The EarlyDetection.com.au telehealth service, developed in partnership with Medmate, launched on 12 May 2026 as an additional medically supported pathway for eligible patients to access BCAL’s tests. Dr Martin A. Devitt has been appointed Medical Director of the Centre for Early Detection, strengthening the clinical governance framework as the company broadens patient access.
The EarlyDetection platform has also been registered in New Zealand, the United Kingdom, the United States, India, and additional international markets, establishing the foundation for BCAL’s longer-term global access strategy.
Jayne Shaw, Executive Chair
“This is an important commercialisation milestone for BCAL as we scale distribution of our early detection tests through existing healthcare workflows. Our GP, specialist, telehealth and clinic channels are designed to make it easier for clinicians and patients to access BCAL’s test portfolio, supporting broader national adoption of blood-based early cancer detection.”
Why early cancer detection through blood tests is a significant market opportunity
Blood-based early cancer detection refers to the use of a simple blood draw to identify biological signals associated with cancer, often before symptoms appear. Detecting cancer at an early stage is associated with significantly better patient outcomes and lower treatment costs, making it a clinically and economically important area of healthcare.
For diagnostic companies, the GP referral pathway is the critical commercial gateway. Most patients do not self-refer for cancer screening tests. Instead, their general practitioner assesses their risk profile and generates a referral. By embedding its referral forms directly into the software a GP uses every day, BCAL removes friction from the referral process and places its tests at the point where clinical decisions are made.
BCAL’s current and forthcoming test portfolio spans multiple cancer types, as summarised below.
| Test Name | Cancer Target | Status | Key Market | Addressable Market Note |
|---|---|---|---|---|
| BREASTESTplus™ | Breast | Available | Australia | Dense breast / rule-out use |
| Avantect® Pancreatic | Pancreatic | Available | Australia / NZ | >A$250M p.a. (Australian market, as previously estimated by BCAL) |
| Avantect® Ovarian | Ovarian | Available | Australia / NZ | — |
| Avantect® Multi-Cancer | Multiple cancers | Launching June 2026 | Australia / NZ | Not disclosed |
BCAL holds an exclusive licence with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of the Avantect® Pancreatic, Avantect® Ovarian, and Avantect® multi-cancer blood tests in Australia and New Zealand. The pancreatic cancer addressable market alone has been previously estimated by BCAL at greater than A$250 million per annum in Australia, and the multi-cancer test arriving in June 2026 is expected to expand that total addressable market further.
The next major ASX story will hit our subscribers first
What’s next: multi-cancer test launch and international expansion
The near-term catalyst for BCAL is the scheduled June 2026 launch of the Avantect® multi-cancer early detection test in the Australian market. This will add a fourth test to the company’s portfolio and is expected to be accessible through the same GP, specialist, and telehealth referral channels now established.
The forthcoming Sydney CBD Centre for Early Detection clinic will serve high-risk patients, providing medical consultation, risk assessment, and direct access to blood-based testing. This adds a direct patient touchpoint to complement the clinician-driven referral model.
International market registrations across New Zealand, the United Kingdom, the United States, India, and additional territories represent optionality rather than confirmed revenue at this stage. They do, however, establish the platform infrastructure needed to pursue global distribution if and when commercial conditions support it.
Key milestones investors may wish to monitor include:
- Avantect® multi-cancer test launch — June 2026
- Sydney CBD Centre for Early Detection clinic opening — timing to be confirmed
- International market development across registered territories
- Adoption metrics across GP, specialist, and telehealth channels
Taken together, this announcement positions BCAL as a multi-channel, multi-test early detection platform, with national GP coverage, specialist integration, telehealth, clinic access, and international registrations all activated concurrently.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ subscribers staying ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.